Latest Intelligence on Pharmaceutical Manufacturers in Canada

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Janssen-Cilag: Stelara set to shine for psoriasis

Janssen-Cilag's Stelara has received European approval for the treatment of moderate to severe plaque psoriasis in adults refractory or intolerant to other systemic therapies. Having now been approved in both Canada and the EU, Stelara stands to command significant market share if it is approved in the US and fulfils physicians' expectations.

Published By Datamonitor
23 Jan 2009
CommentWire
CommentWire

Nycomed/Merck: Daxas deal will have limited financial impact

Nycomed and Merck & Co. have agreed to co-promote the novel COPD therapy Daxas, which recently gained a positive recommendation in the EU. While this collaboration boosts Daxas' commercial prospects in several European countries, as well as Canada, the drug is limited by its restricted patient potential.

Published By Datamonitor
28 Apr 2010
CommentWire
CommentWire

Johnson & Johnson: Remicade gains another indication

Pediatric patients in Canada will become the first to have access to Remicade for treating moderately to severely active ulcerative colitis, following Health Canada's approval of the drug for this indication. The regulator's decision is likely to pave the way for similar indication extensions for children in other markets.

Published By Datamonitor
05 Sep 2011

« | 1 | 2 | » »|

No help is available.